Trade Myriad Genetics Inc - MYGN CFD

Myriad Genetics Company profile

About Myriad Genetics, Inc.

Myriad Genetics, Inc. (Myriad) is a genetic testing and precision medicine company. Myriad is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can progress patient care. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. The Company's products include myRisk, BRACAnalysis, BRACAnalysis CDx myChoice CDx, Prolaris, EndoPredict, Foresight and Prequel.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Myriad Genetics, Inc. revenues increased from $299.8M to $690.6M. Net loss before extraordinary items decreased 67% to $24.5M. Revenues reflect Molecular diagnostic testing increase from $279.6M to $666.4M, Pharmaceutical And Clinical Services increase of 20% to $24.2M. Lower net loss reflects Other income (expense) increase from $1.2M (expense) to $139.3M (income).

Equity composition

Common Stock $.01 Par, 04/11, 150M auth., 85,735,872 o/s. Insiders & strategic holders own 0.38%. IPO 10/95, 2.6M shares @ $18 by Cowen & Co. PO 11/02, 3M shs @ $19.50 by Morgan Stanley. All Preferred Stock converted into Common upon completion of IPO. 03/2009, 2-for-1 Stock split.